4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Axsome Therapeutics, Inc. (AXSM) operates in the Biotechnology industry and is headquartered in New York, United States with about 1,220 employees. Its market capitalization is roughly $12 billion. In the fiscal year ended 2025-12-31, AXSM reported $638M in revenue and ($183M) in net income.
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
Interactive charts & full statements → Open the AXSM valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $638M | $386M | $271M | $50M | — |
| Gross Profit | $591M | $352M | $244M | $45M | — |
| Operating Income (EBIT) | ($169M) | ($252M) | ($183M) | ($176M) | — |
| Net Income | ($183M) | ($287M) | ($239M) | ($187M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $191M | $196M | $171M | $150M | $122M |
| Gross Profit | $176M | $184M | $159M | $137M | $112M |
| Operating Income (EBIT) | ($63M) | ($36M) | ($33M) | ($45M) | ($56M) |
| Net Income | ($64M) | ($29M) | ($47M) | ($48M) | ($59M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $690M | $568M | $588M | $332M | — |
| Total Liabilities | $602M | $512M | $397M | $222M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AXSM viewer.
About TickerBase · Data methodology & sources